Immortalized erythroid cells as a novel frontier for in vitro blood production: current approaches and potential clinical application.
Cell differentiation
Erythroblasts
Erythropoiesis
Genetic engineering
Hematopoietic stem cells
Immortalization
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
24 05 2023
24 05 2023
Historique:
received:
17
01
2023
accepted:
05
05
2023
medline:
26
5
2023
pubmed:
25
5
2023
entrez:
24
5
2023
Statut:
epublish
Résumé
Blood transfusions represent common medical procedures, which provide essential supportive therapy. However, these procedures are notoriously expensive for healthcare services and not without risk. The potential threat of transfusion-related complications, such as the development of pathogenic infections and the occurring of alloimmunization events, alongside the donor's dependence, strongly limits the availability of transfusion units and represents significant concerns in transfusion medicine. Moreover, a further increase in the demand for donated blood and blood transfusion, combined with a reduction in blood donors, is expected as a consequence of the decrease in birth rates and increase in life expectancy in industrialized countries. An emerging and alternative strategy preferred over blood transfusion is the in vitro production of blood cells from immortalized erythroid cells. The high survival capacity alongside the stable and longest proliferation time of immortalized erythroid cells could allow the generation of a large number of cells over time, which are able to differentiate into blood cells. However, a large-scale, cost-effective production of blood cells is not yet a routine clinical procedure, as being dependent on the optimization of culture conditions of immortalized erythroid cells. In our review, we provide an overview of the most recent erythroid cell immortalization approaches, while also describing and discussing related advancements of establishing immortalized erythroid cell lines.
Sections du résumé
BACKGROUND
Blood transfusions represent common medical procedures, which provide essential supportive therapy. However, these procedures are notoriously expensive for healthcare services and not without risk. The potential threat of transfusion-related complications, such as the development of pathogenic infections and the occurring of alloimmunization events, alongside the donor's dependence, strongly limits the availability of transfusion units and represents significant concerns in transfusion medicine. Moreover, a further increase in the demand for donated blood and blood transfusion, combined with a reduction in blood donors, is expected as a consequence of the decrease in birth rates and increase in life expectancy in industrialized countries.
MAIN BODY
An emerging and alternative strategy preferred over blood transfusion is the in vitro production of blood cells from immortalized erythroid cells. The high survival capacity alongside the stable and longest proliferation time of immortalized erythroid cells could allow the generation of a large number of cells over time, which are able to differentiate into blood cells. However, a large-scale, cost-effective production of blood cells is not yet a routine clinical procedure, as being dependent on the optimization of culture conditions of immortalized erythroid cells.
CONCLUSION
In our review, we provide an overview of the most recent erythroid cell immortalization approaches, while also describing and discussing related advancements of establishing immortalized erythroid cell lines.
Identifiants
pubmed: 37226267
doi: 10.1186/s13287-023-03367-8
pii: 10.1186/s13287-023-03367-8
pmc: PMC10210309
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
139Informations de copyright
© 2023. The Author(s).
Références
J Cell Physiol. 2018 Jan;234(1):100-107
pubmed: 30078192
Exp Hematol. 2019 Jun;74:19-24.e4
pubmed: 31004744
Cells. 2021 Mar 01;10(3):
pubmed: 33804564
Front Cell Infect Microbiol. 2022 Nov 14;12:1039520
pubmed: 36452302
Stem Cell Res Ther. 2020 Nov 16;11(1):483
pubmed: 33198819
Cells. 2022 Feb 05;11(3):
pubmed: 35159366
Blood. 2008 Feb 15;111(4):2409-17
pubmed: 18032705
Haematologica. 2010 Sep;95(9):1594-8
pubmed: 20378567
J Dermatol Sci. 2020 Dec;100(3):223-226
pubmed: 32998835
Exp Hematol. 2012 Jun;40(6):466-76
pubmed: 22421183
Crit Care Nurs Q. 2019 Apr/Jun;42(2):187-191
pubmed: 30807343
Hum Cell. 2022 Jan;35(1):408-417
pubmed: 34817797
Blood. 2012 Jun 21;119(25):6118-27
pubmed: 22461493
PLoS One. 2008 Feb 06;3(2):e1544
pubmed: 18253492
Nat Commun. 2014 Jul 14;5:4372
pubmed: 25019369
Cell. 1993 Nov 5;75(3):495-505
pubmed: 8221889
J Biol Chem. 2010 Dec 17;285(51):40252-65
pubmed: 20940306
Blood Rev. 2021 Mar;46:100740
pubmed: 32798012
Curr Opin Hematol. 2017 May;24(3):159-166
pubmed: 28099275
Blood Adv. 2019 Nov 12;3(21):3337-3350
pubmed: 31698463
Biochem Res Int. 2011;2011:373859
pubmed: 21490703
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
IUBMB Life. 2020 Jan;72(1):89-105
pubmed: 31769197
Stem Cells Transl Med. 2017 Aug;6(8):1698-1709
pubmed: 28618139
Exp Hematol. 2019 Jan;69:11-16
pubmed: 30326248
Int J Biol Sci. 2013 May 08;9(5):435-43
pubmed: 23678293
Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):100-103
pubmed: 34485826
N Engl J Med. 1998 Nov 26;339(22):1565-77
pubmed: 9828244
Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9797-802
pubmed: 10449774
Blood. 2012 Jan 26;119(4):1036-44
pubmed: 22049517
Protein Cell. 2020 Jan;11(1):34-44
pubmed: 31201709
Exp Hematol. 2010 Nov;38(11):994-1005.e1-2
pubmed: 20696208
Nature. 2008 Jul 10;454(7201):226-31
pubmed: 18568025
Blood. 2010 Oct 28;116(17):3331-40
pubmed: 20644112
PLoS One. 2013;8(3):e59890
pubmed: 23533656
Int Rev Cell Mol Biol. 2015;316:159-82
pubmed: 25805124
Mol Ther. 2014 Feb;22(2):451-463
pubmed: 24002691
Transfusion. 2008 Jun;48(6):1122-32
pubmed: 18298595
Stem Cells Dev. 2011 Sep;20(9):1639-47
pubmed: 21434814
Immunity. 1996 Jan;4(1):97-106
pubmed: 8574856
Stem Cell Res Ther. 2018 Feb 26;9(1):46
pubmed: 29482624
Nature. 2003 Jan 30;421(6922):547-51
pubmed: 12540851
Front Microbiol. 2020 Nov 19;11:591452
pubmed: 33329471
Mol Med. 2004 Jul-Dec;10(7-12):112-6
pubmed: 15702218
BJOG. 2018 Mar;125(4):478-486
pubmed: 29266694
Leuk Res. 2013 Jun;37(6):681-9
pubmed: 23473917
Oncogene. 2022 Jan;41(3):301-308
pubmed: 34750517
Blood. 2022 Apr 21;139(16):2450-2459
pubmed: 34936695
Int Immunol. 2011 Jan;23(1):65-74
pubmed: 21135032
Leukemia. 2021 Jul;35(7):1873-1889
pubmed: 33958699
Blood. 2001 Nov 15;98(10):2894-9
pubmed: 11698268
Mol Ther Methods Clin Dev. 2021 Jun 12;22:26-39
pubmed: 34485592
Leukemia. 2010 Jul;24(7):1249-57
pubmed: 20520638
Front Cell Dev Biol. 2021 Feb 12;8:613885
pubmed: 33644032
Nat Commun. 2017 Mar 14;8:14750
pubmed: 28290447
Pathogens. 2020 Mar 18;9(3):
pubmed: 32197385
PLoS One. 2014 Jul 14;9(7):e100874
pubmed: 25019302
Nature. 2005 Sep 29;437(7059):754-8
pubmed: 16193055
Stem Cells. 2005 Oct;23(9):1423-33
pubmed: 16144874
Blood. 1994 Nov 15;84(10):3494-504
pubmed: 7949103
Expert Opin Biol Ther. 2017 Jun;17(6):691-699
pubmed: 28379044
PLoS One. 2011;6(11):e27956
pubmed: 22132178
Int J Stem Cells. 2016 May 30;9(1):53-9
pubmed: 27426086
Blood. 1995 Jan 1;85(1):275-82
pubmed: 7528570
Crit Care Nurs Q. 2019 Apr/Jun;42(2):173-176
pubmed: 30807341
Exp Hematol. 2020 Nov;91:10-21
pubmed: 32910996
Biotechnol J. 2018 Apr;13(4):e1700567
pubmed: 29330927
Trends Cell Biol. 2011 Jul;21(7):409-15
pubmed: 21592797
J Clin Med. 2022 May 19;11(10):
pubmed: 35628985
Blood. 2010 Mar 11;115(10):2021-7
pubmed: 20038785
Science. 2016 Jan 8;351(6269):aab2116
pubmed: 26541609
Nat Cell Biol. 2008 Mar;10(3):314-21
pubmed: 18264091
Exp Hematol. 2019 Mar;71:32-42
pubmed: 30664904
Int J Mol Sci. 2021 Oct 24;22(21):
pubmed: 34768895
Cold Spring Harb Perspect Med. 2013 Apr 01;3(4):a011601
pubmed: 23545573
Vaccines (Basel). 2020 Aug 25;8(3):
pubmed: 32854278
Blood. 1995 Feb 1;85(3):790-8
pubmed: 7530509
Pathogens. 2021 Dec 17;10(12):
pubmed: 34959588
Front Oncol. 2019 Jul 25;9:670
pubmed: 31403031
Int J Mol Sci. 2020 Dec 08;21(24):
pubmed: 33302450
Front Physiol. 2014 Jan 28;5:3
pubmed: 24478716
Front Oncol. 2022 Mar 08;12:832047
pubmed: 35350569
Exp Hematol. 2021 Mar;95:13-22
pubmed: 33440185
J Neurovirol. 2004 Aug;10(4):250-4
pubmed: 15371155
Exp Hematol. 2000 Dec;28(12):1343-53
pubmed: 11146156
Blood Adv. 2017 May 26;1(14):867-874
pubmed: 29296730
Infect Agent Cancer. 2020 Apr 01;15:20
pubmed: 32266002
Front Physiol. 2014 Jan 30;5:9
pubmed: 24523696
Biotechnol Adv. 2018 Dec;36(8):2118-2128
pubmed: 30273713
Membranes (Basel). 2022 Mar 10;12(3):
pubmed: 35323786
Sci Rep. 2020 Jul 16;10(1):11806
pubmed: 32678227
Stem Cells Dev. 2019 Dec 1;28(23):1540-1551
pubmed: 31595840
Transfus Apher Sci. 2019 Feb;58(1):108-112
pubmed: 30616958
Cancers (Basel). 2022 Feb 22;14(5):
pubmed: 35267424
J Cell Biol. 1967 Oct;35(1):237-45
pubmed: 6061718
Stem Cell Reports. 2013 Dec 05;1(6):499-508
pubmed: 24371805
Transfus Med Rev. 2019 Jan;33(1):43-50
pubmed: 30528986
Cell Death Dis. 2019 Nov 26;10(12):889
pubmed: 31767857
Front Microbiol. 2021 Dec 14;12:789991
pubmed: 34970247
Sci Rep. 2015 Jul 09;5:12065
pubmed: 26156589
Sci Rep. 2020 Oct 8;10(1):16798
pubmed: 33033327
J Exp Med. 1995 Jan 1;181(1):411-5
pubmed: 7528776
Tissue Eng Part C Methods. 2011 Nov;17(11):1131-7
pubmed: 21736478
Sci Rep. 2022 Jun 1;12(1):9151
pubmed: 35650226
N Engl J Med. 1957 Sep 12;257(11):491-6
pubmed: 13464965
Microorganisms. 2022 Jun 10;10(6):
pubmed: 35744711